Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3189966 | 1.00 | LMNA (0.38) | LMNAALOX15HSD17B10ALDH1A1TSHR | |
| SCHEMBL21116679 | 0.95 | LMNA (0.35) | LMNAALOX15HSD17B10 | |
| SCHEMBL316986 | 0.78 | LMNA (0.50) | LMNAALOX15HSD17B10ALDH1A1TSHR | |
| SCHEMBL1661967 | 0.78 | LMNA (0.50) | LMNAALOX15HSD17B10ALDH1A1TSHR | |
| SCHEMBL345324 | 0.78 | LMNA (0.50) | LMNAALOX15HSD17B10ALDH1A1TSHR | |
| SCHEMBL16625654 | 0.77 | LMNA (0.36) | LMNAALOX15HSD17B10 | |
| SCHEMBL22193124 | 0.77 | — | — | |
| SCHEMBL28414100 | 0.76 | LMNA (0.40) | LMNAALOX15HSD17B10ALDH1A1TSHR | |
| SCHEMBL465616 | 0.74 | — | — | |
| SCHEMBL22193114 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017101793-A1 | 1, 3, 4-SELENADIAZOLE COMPOUNDS WITH PHARMACOLOGICAL ACTIVITY | HANGZHOU JENNIFER BIOTECH CO., LTD. (CN) | 2017-06-22 | — | — | WO | disclosed |
| US-20170173559-A1 | A POROUS METAL-ORGANIC FRAMEWORK WITH PYRIMIDINE GROUPS FOR METHANE STORAGE EXHIBITING HIGH WORKING CAPACITY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173559-A1 | A POROUS METAL-ORGANIC FRAMEWORK WITH PYRIMIDINE GROUPS FOR METHANE STORAGE EXHIBITING HIGH WORKING CAPACITY | MTHFD1, MRPS9, YTHDF2 | LMNA 3575/4885ALOX15 1580/4885HSD17B10 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.